Your browser doesn't support javascript.
loading
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper, Marius M; Al-Hiti, Hikmet; Benza, Raymond L; Chang, Sung-A; Corris, Paul A; Gibbs, J Simon R; Grünig, Ekkehard; Jansa, Pavel; Klinger, James R; Langleben, David; McLaughlin, Vallerie V; Meyer, Gisela M B; Ota-Arakaki, Jaquelina; Peacock, Andrew J; Pulido, Tomás; Rosenkranz, Stephan; Vizza, Carmine Dario; Vonk-Noordegraaf, Anton; White, R James; Chang, Mikyung; Kleinjung, Frank; Meier, Christian; Paraschin, Karen; Ghofrani, Hossein Ardeschir; Simonneau, Gérald.
Afiliação
  • Hoeper MM; Clinic for Respiratory Medicine, Hannover Medical School, member of the German Center for Lung Research (DZL), Hannover, Germany. Electronic address: Hoeper.Marius@mh-hannover.de.
  • Al-Hiti H; Department of Cardiology, Institute of Clinical and Experimental Medicine-IKEM, Prague, Czech Republic.
  • Benza RL; Division of Cardiovascular Diseases, Ohio State University, Columbus, OH, USA.
  • Chang SA; Division of Cardiology, Department of Medicine, Heart Vascular and Stroke Institute Imaging Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, South Korea.
  • Corris PA; Institute of Cellular Medicine, Newcastle University, Newcastle, UK.
  • Gibbs JSR; National Heart and Lung Institute, Imperial College London, and Department of Cardiology, National Pulmonary Hypertension Service, Hammersmith Hospital, London, UK.
  • Grünig E; Centre for Pulmonary Hypertension, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center (TLRC), member of DZL, Heidelberg, Germany.
  • Jansa P; 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic.
  • Klinger JR; Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA.
  • Langleben D; Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada.
  • McLaughlin VV; Division of Cardiovascular Medicine, University of Michigan, Michigan Medicine, Ann Arbor, MI, USA.
  • Meyer GMB; Centro de Hipertensão Pulmonar, Complexo Hospitalar Santa Casa de Porto Alegre, Porto Alegre, Brazil.
  • Ota-Arakaki J; Pulmonary Circulation Group, Department of Medicine, Universidade Federal de São Paulo-Hospital São Paulo, São Paulo, Brazil.
  • Peacock AJ; Scottish Pulmonary Vascular Unit, Regional Lung and Heart Centre, Glasgow, UK.
  • Pulido T; Cardiopulmonary Department, National Heart Institute, Mexico City, Mexico.
  • Rosenkranz S; Clinic III for Internal Medicine (Cardiology), Cologne Cardiovascular Research Center (CCRC), and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
  • Vizza CD; Pulmonary Hypertension Unit, Department of Cardiovascular and Respiratory Disease, La Sapienza University of Rome, Rome, Italy.
  • Vonk-Noordegraaf A; Department of Pneumology, VU University Medical Center, Amsterdam, Netherlands.
  • White RJ; University of Rochester Medical Center, Rochester, NY, USA.
  • Chang M; Global Medical Affairs, Bayer AG, Berlin, Germany.
  • Kleinjung F; Global Medical Affairs, Bayer AG, Berlin, Germany.
  • Meier C; Global Medical Affairs, Bayer AG, Berlin, Germany.
  • Paraschin K; Bayer AG, São Paulo, Brazil.
  • Ghofrani HA; University of Giessen and Marburg Lung Center, member of DZL, Giessen, Germany; Department of Pneumology, Kerchoff Clinic, Bad Nauheim, Germany; Department of Medicine, Imperial College London, London, UK.
  • Simonneau G; Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Saclay, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and Inserm U999, Le Kremlin-Bicêtre, France.
Lancet Respir Med ; 9(6): 573-584, 2021 06.
Article em En | MEDLINE | ID: mdl-33773120
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Inibidores da Fosfodiesterase 5 / Hipertensão Arterial Pulmonar Tipo de estudo: Clinical_trials / Guideline / Observational_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Respir Med Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Inibidores da Fosfodiesterase 5 / Hipertensão Arterial Pulmonar Tipo de estudo: Clinical_trials / Guideline / Observational_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Respir Med Ano de publicação: 2021 Tipo de documento: Article